Interacción entre polimorfismos en los genes slc6a4 y bdnf en depresión mayor en una muestra de la población argentina
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v38i1.586Palabras clave:
depresión mayor, polimorfismos, serotonina, BDNF, APOEResumen
La disfunción en la neurotransmisión serotoninérgica ha sido clásicamente asociada con el trastorno depresivo mayor (TDM); sin embargo, otras vías y procesos parecerían tener un rol en esta enfermedad, como la neurogénesis y moléculas asociadas: el factor neurotrófico derivado del cerebro (BDNF) y la apoliproteína E (APOE). Existen reportes en los que se establecen asociaciones entre polimorfismos en estos genes y el TDM. El objetivo de nuestro trabajo fue analizar la posible asociación entre el TDM y polimorfismos en los genes HTR2A (receptor 5-hidroxitriptamina 2A), BDNF y APOE en una muestra de la población argentina previamente estudiada para 2 polimorfismos en el gen SLC6A4 (transportador soluble familia 6 miembro 4). Se estudiaron 5 polimorfismos (rs6311 y rs6313 en HTR2A; rs429358 y rs7412 en APOE; rs6265 en BDNF) en 95 pacientes con TDM y 107 controles no relacionados. No se observaron diferencias significativas entre grupos al analizar la asociación por regresión logística con un único marcador; cuando se analizó el posible efecto combinatorio de polimorfismos (incluyendo los previamente estudiados para el gen SCL6A4) usando un modelo dominante para los alelos de riesgo, los genotipos L/S_10/12_G/A (OR=3,57(95%CI=1,43-8,93); p=0,004, valor-p-ajustado=0,01) en SLC6A4 y BDNF y L/S_10/12_T/C_3/3_G/A en SLC6A4, HTR2A, APOE y BDNF (OR=5,99(95%CI=1,66-21,56); p=0,002, valor-p-ajustado=0,07), fueron más prevalentes en pacientes que controles (20%vs.6% y 15%vs.3% respectivamente). Si bien es necesario replicar estos hallazgos en una población más grande, nuestros resultados sugieren una posible interacción entre moléculas involucradas en la neurogénesis (BDNF y APOE), la neurotransmisión serotoninérgica (SLC6A4 y HTR2A) y la patogenia de la depresión mayor.
Descargas
Referencias
Lesch KP, Balling U, Gross J, et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95(2):157-162. DOI: https://doi.org/10.1007/BF01276434
Heils a, Teufel a, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem . 1996;66(6):2621-2624. DOI: https://doi.org/10.1046/j.1471-4159.1996.66062621.x
Hu X-Z, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78(5):815-826. DOI: https://doi.org/10.1086/503850
Van Dyck CH, Malison RT, Staley JK, et al. Central Serotonin Transporter Availability Measured with [123I]beta-CIT SPECT in Relation to Serotonin Transporter Genotype. Am J Psychiatry. 2004;161(3):525-531. DOI: https://doi.org/10.1176/appi.ajp.161.3.525
Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry. 2008;13(2):131-146. DOI: https://doi.org/10.1038/sj.mp.4002067
Jaworska N, MacMaster FP, Foster J, et al. The influence of 5-HTTLPR and Val66Met polymorphisms on cortical thickness and volume in limbic and paralimbic regions in depression: a preliminary study. BMC Psychiatry. 2016 Mar;16:61. DOI: https://doi.org/10.1186/s12888-016-0777-x
Cajal AR, Redal MA, Costa LD, et al. Influence of 5-HTTLPR and 5-HTTVNTR polymorphisms of the serotonin transporter gene (SLC6A4) on major depressive disorder in a sample of Argentinean population. Psychiatr Genet. 2012;22(2):103-104. DOI: https://doi.org/10.1097/YPG.0b013e32834acc9b
Husain MM, McDonald WM, Doraiswamy PM, et al. A magnetic resonance imaging study of putamen nuclei in major depression. Psychiatry Res. 1991 Oct;40(2):95-99. DOI: https://doi.org/10.1016/0165-1781(91)90149-J
Fukuda Y, Koga M, Arai M, et al. Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes. Biol Psychiatry. 2006;60(12):1331-1335. DOI: https://doi.org/10.1016/j.biopsych.2006.06.024
Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004;27(10):589-594. DOI: https://doi.org/10.1016/j.tins.2004.08.001
Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73-83. DOI: https://doi.org/10.1038/sj.npp.1301571
Martinowich K, Manji HK, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089-1093. DOI: https://doi.org/10.1038/nn1971
Guilloux JP, Douillard-Guilloux G, Kota R, et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry. 2012;17(11):1130-1142. DOI: https://doi.org/10.1038/mp.2011.113
Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 2010;15(3):260-271. DOI: https://doi.org/10.1038/mp.2008.109
Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314(5796):140-143. DOI: https://doi.org/10.1126/science.1129663
Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-269. DOI: https://doi.org/10.1016/S0092-8674(03)00035-7
Eaton MJ, Staley JK, Globus MY, et al. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Dev Biol. 1995; 170:169-182. DOI: https://doi.org/10.1006/dbio.1995.1205
Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry. 2006; 59:1116-1127. DOI: https://doi.org/10.1016/j.biopsych.2006.02.013
Dalton ED, Hammen CL, Najman JM, et al. Genetic Susceptibility to Family Environment : BDNF Val66met and 5-HTTLPR Influence Depressive Symptoms. J Fam Psychol. 2014;28(6):947-956. DOI: https://doi.org/10.1037/fam0000032
Colle R, Gressier F, Verstuyft C, et al. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord. 2015;175:233-240. DOI: https://doi.org/10.1016/j.jad.2015.01.013
Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13(8):772-785. DOI: https://doi.org/10.1038/sj.mp.4002088
Feng F, Lu S-S, Hu C-Y, et al. Association between apolipoprotein E gene polymorphism and depression. J Clin Neurosci. 2015;22:1232-1238. DOI: https://doi.org/10.1016/j.jocn.2015.02.012
Surtees PG, Wainwright NW, Bowman R, et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. J Psychiatr Res. 2009;43(9):843-847. DOI: https://doi.org/10.1016/j.jpsychires.2008.12.001
Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum Biol. 1995; 67(2):195-215.
Smith AD, Johnston C, Sim E, et al. Protective effect of apo epsilon 2 in Alzheimer’s disease. Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet (London, England). 1994;344: 473-474.
Rajan KB, Wilson RS, Skarupski KA, et al. Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline. Psychosom Med. 2014 Feb;76(2):101-108. DOI: https://doi.org/10.1097/PSY.0000000000000029
Choi MJ, Lee HJ, Ham BJ, et al. Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene. Neuropsychobiology. 2004;49(1):38-41. DOI: https://doi.org/10.1159/000075337
Wang L, Ashley-Koch A, Steffens DC,et al. Impact of BDNF Val66Met and 5-HTTLPR polymorphism variants on neural substrates related to sadness and executive function. Genes Brain Behav. 2012;11(3):352-359. DOI: https://doi.org/10.1111/j.1601-183X.2012.00764.x
Parsons MJ, D’Souza UM, Arranz MJ, et al. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004;56(6):406-410. DOI: https://doi.org/10.1016/j.biopsych.2004.06.020
Minov C, Baghai TC, Schule C, et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett. 2001;303(2):119-122. DOI: https://doi.org/10.1016/S0304-3940(01)01704-9
Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009;164(1):300-330. DOI: https://doi.org/10.1016/j.neuroscience.2009.03.082
Homberg JR, Molteni R, Calabrese F, et al. The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev. 2014 Jun;43:35-47. DOI: https://doi.org/10.1016/j.neubiorev.2014.03.012
Harkness KL, Strauss J, Michael Bagby R, et al. Interactions between childhood maltreatment and brain-derived neurotrophic factor and serotonin transporter polymorphisms on depression symptoms. Psychiatry Res. 2015; 229(1-2):609-612. DOI: https://doi.org/10.1016/j.psychres.2015.04.040
Kostic M, Canu E, Agosta F, et al. The Cumulative Effect of Genetic Polymorphisms on Depression and Brain Structural Integrity. Hum Brain Mapp. 2016;37(6):2173-2184. DOI: https://doi.org/10.1002/hbm.23165
Descargas
Compartir artículo
Publicado
Número
Sección
Licencia
Derechos de autor 2018 Revista del Hospital Italiano de Buenos Aires
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
